Premier, Inc. recently released updated inflation estimates for contracted and non-contracted pharmaceutical pricing for fiscal year 2020 and said most of the overall pharmaceutical inflation comes from new drugs (2.8%), including cellular and gene therapies.
Premier, Inc. recently released updated inflation estimates for contracted and non-contracted pharmaceutical pricing for fiscal year 2020 and said most of the overall pharmaceutical inflation comes from new drugs (2.8%), including cellular and gene therapies.
The company is projecting a 4.2% increase in total pharmaceutical costs for non-disproportionate share (DSH) hospitals and 3.8% for DSH-eligible facilities.
The new estimate is approximately 0.4% higher than projections from earlier this year. The new fiscal year began in July and ends at the end of June 2020.
“Pharmaceuticals are responsible for a large and growing share of the total hospital budget,” Michael J. Alkire, the president of Premier, said in a statement. “New drugs, while offering tremendous potential to cure or curb the spread of disease, are often introduced at price points that can have an adverse effect on health system margins. As one of the nation’s leading group purchasing organizations, our contracting team has been relentless in working to hold these costs down, putting manufacturers in head-to-head competition with one another to win our business, using technology and 100 billion data points to assure value and smart decisions. We have also been actively pursuing value-based contracts with manufacturers, which would hold drug makers accountable for delivering the outcomes promised in their marketing.”
In an email with The Center for Biosimilars®, Sonia T. Oskouei, PharmD, BCMAS, DPLA, Premier’s vice president of innovation and solution development, elaborated on the report as well as the company’s pursuit of value-based contracts.
The 2.8% for new drugs is the same as 6 months ago, she said, while price inflation rose from 2% to 2.4% from earlier this year.
Premier’s members are coping with higher costs by managing “drug therapy through a formulary system in which their pharmacists work with physicians to manage patient treatment strategies, and they use lower-cost alternatives, such as generics and biosimilars, when possible,” Oskouei said.
A year ago, a Premier survey showed that 73% of healthcare providers rank value-based contracting with suppliers as a priority for improving return on investments, she said.
Premier works with its members to develop and deploy value-based contracts across a range of suppliers and product lines. “To date we have two pharmaceutical value-based contracts that have been executed,” Oskouei said. “Premier continues to negotiate a range of value-based contracts with suppliers.”
“Value-based contracts hold a lot of potential, but there are regulatory barriers that stand in the way of making them pervasive in the acute care setting,” she added. She noted that value-based contracts are more common for devices and for pharmaceutical arrangements with payers, which don’t face the same regulatory burdens as providers.
“However, we are actively working to level the playing field such that these contracts can become more commonplace in the acute care setting, and our hope is that they ultimately will be a valuable tool in managing total costs.”
There are several challenges to enacting value-based arrangements. Providers are currently constrained by the Stark Law, which was enacted to prevent financial incentives from influencing how providers refer patients for services in a fee-for-service system. CMS has been looking to speed the transition to value-based care by giving providers more flexibility to make referrals. Anti-kickback statutes and the Medicaid best price rule are some others.
In its statement, Premier cited a number of actions that would assist with creating a more competitive pharmaceutical market, including the following:
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.